Roche has announced that its phase 3 IMpower130 study met its co-primary endpoints of overall survival (OS) and progression-free survival (PFS) in non-small cell lung cancer (NSCLC). The combination ...
The FDA has approved a combination of Pfizer’s Braftovi and Merck KGaA’s Erbitux for a form of untreated metastatic colorectal cancer, the first targeted drug regimen for this form of the disease.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback